Neoadjuvant semaglutide showed no benefit in weight loss, diabetes remission or safety in a cohort of patients who underwent ...

Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for ...

Peptides are gaining traction for everything from the potential of muscle recovery to brain support—but as they show up in ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Their project, called Phytogene, harnesses the power of “biopharming” — a method that transforms plants into living drug ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even ...

The cohort study used data from the TriNetX database, encompassing patients diagnosed with diabetes and prescribed ...

Davis also recommends that his patients adopt a "hearty diet" consisting of fiber, protein and nutritious foods to ensure proper nourishment while taking a semaglutide medication. "Not only may ...